PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
PD1 antibody is now recommended for dMMR/MSI-H metastatic colorectal cancer patients as
second line. Chemoradiotherapy is standand treatment for locally advanced rectal cancer and
is also recommended as an alternative choice for unresectable locally advanced colon cancer.
Thus, this study will investigate the efficacy and toxicity of combination strategy using PD1
antibody and chemoradiotherapy for dMMR/MSI-H locally advnaced colorectal cancer patients.